Romero-Gómez M et al. |
Three-day intravenous triple therapy is not effective for the eradication of Helicobacter pylori infection in patients with bleeding gastro-duodenal ulcer. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14616169
|
Cardenas VM et al. |
Rabeprazole containing triple therapy to eradicate Helicobacter pylori infection on the Texas-Mexican border. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:16393310
|
Gatta L et al. |
A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15963079
|
Thijs JC et al. |
Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. |
1994 |
Aliment. Pharmacol. Ther. |
pmid:8186339
|
Kamada T et al. |
The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12869086
|
Neri M et al. |
Role of antibiotic sensitivity testing before first-line Helicobacter pylori eradication treatments. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535876
|
Logan RP et al. |
Eradication of Helicobacter pylori and prevention of recurrence of duodenal ulcer: a randomized, double-blind, multi-centre trial of omeprazole with or without clarithromycin. |
1995 |
Aliment. Pharmacol. Ther. |
pmid:8527618
|
Lai KC et al. |
Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users--a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:14535877
|
Gisbert JP et al. |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10540045
|
Bruley Des Varannes S et al. |
There are some benefits for eradicating Helicobacter pylori in patients with non-ulcer dyspepsia. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11472320
|
Adachi K et al. |
Efficacy of ecabet sodium for Helicobacter pylori eradication triple therapy in comparison with a lansoprazole-based regimen. |
2001 |
Aliment. Pharmacol. Ther. |
pmid:11472321
|
Okudaira K et al. |
Concomitant dosing of famotidine with a triple therapy increases the cure rates of Helicobacter pylori infections in patients with the homozygous extensive metabolizer genotype of CYP2C19. |
2005 |
Aliment. Pharmacol. Ther. |
pmid:15710002
|
Gschwantler M et al. |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10468682
|
Paré P et al. |
Comparison of ranitidine bismuth citrate plus clarithromycin with omeprazole plus clarithromycin for the eradication of Helicobacter pylori. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10468683
|
Lane JA et al. |
Randomised clinical trial: Helicobacter pylori eradication is associated with a significantly increased body mass index in a placebo-controlled study. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21366634
|
Sasaki A et al. |
Long-term observation of reflux oesophagitis developing after Helicobacter pylori eradication therapy. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12823156
|
Sung JJ et al. |
One-week use of ranitidine bismuth citrate, amoxycillin and clarithromycin for the treatment of Helicobacter pylori-related duodenal ulcer. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9726384
|
Pazzi P et al. |
Short-term low-dose pantoprazole-based triple therapy for cure of Helicobacter pylori infection in duodenal ulcer patients. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9726385
|
Azuma T et al. |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10807427
|
Talley NJ et al. |
Nizatidine in combination with amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678811
|
Ricciardiello L et al. |
Efficacy and safety of three 7-day Helicobacter pylori eradication regimens containing ranitidine bismuth citrate. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678812
|
Cammarota G et al. |
One-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus medium-dose clarithromycin and either tinidazole or amoxycillin. |
1998 |
Aliment. Pharmacol. Ther. |
pmid:9678813
|
Barth J and Hahne W |
Review article: rabeprazole-based therapy in Helicobacter pylori eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849125
|
Qasim A and O'Morain CA |
Review article: treatment of Helicobacter pylori infection and factors influencing eradication. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11849124
|
Yousfi MM et al. |
One-week triple therapy with omeprazole, amoxycillin and clarithromycin for treatment of Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8853767
|
Gisbert JP and Calvet X |
Review article: non-bismuth quadruple (concomitant) therapy for eradication of Helicobater pylori. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21745241
|
Hawkey CJ et al. |
Safety and efficacy of 7-day rabeprazole- and omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with documented peptic ulcer disease. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12694089
|
John Albert M et al. |
High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait. |
2006 |
Aliment. Pharmacol. Ther. |
pmid:17059517
|
Villoria A et al. |
Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18644011
|
Furuta T et al. |
Effect of MDR1 C3435T polymorphism on cure rates of Helicobacter pylori infection by triple therapy with lansoprazole, amoxicillin and clarithromycin in relation to CYP 2C19 genotypes and 23S rRNA genotypes of H. pylori. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17697203
|
Kashimura H et al. |
Polaprezinc, a mucosal protective agent, in combination with lansoprazole, amoxycillin and clarithromycin increases the cure rate of Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10215732
|
Kim YS et al. |
Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea. |
2011 |
Aliment. Pharmacol. Ther. |
pmid:21923713
|
Leiper K et al. |
Clinical trial: randomized study of clarithromycin versus placebo in active Crohn's disease. |
2008 |
Aliment. Pharmacol. Ther. |
pmid:18315579
|
Thung I et al. |
Review article: the global emergence of Helicobacter pylori antibiotic resistance. |
2016 |
Aliment. Pharmacol. Ther. |
pmid:26694080
|
Ford AC et al. |
Clinical trial: knowledge of negative Helicobacter pylori status reduces subsequent dyspepsia-related resource use. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17944741
|
Graham DY et al. |
Ranitidine bismuth citrate, tetracycline, clarithromycin twice-a-day triple therapy for clarithromycin susceptible Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102946
|
Zanten SJ et al. |
The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102960
|
Pilotto A and Malfertheiner P |
Review article: an approach to Helicobacter pylori infection in the elderly. |
2002 |
Aliment. Pharmacol. Ther. |
pmid:11929385
|
Van der Wouden EJ et al. |
The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection. |
1999 |
Aliment. Pharmacol. Ther. |
pmid:10102961
|
Laine L et al. |
A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354200
|
Rinaldi V et al. |
The management of failed dual or triple therapy for Helicobacter pylori eradication. |
1997 |
Aliment. Pharmacol. Ther. |
pmid:9354202
|
Nista EC et al. |
Levofloxacin-based triple therapy vs. quadruple therapy in second-line Helicobacter pylori treatment: a randomized trial. |
2003 |
Aliment. Pharmacol. Ther. |
pmid:12969089
|
Peterson WL et al. |
Ranitidine bismuth citrate plus clarithromycin is effective for healing duodenal ulcers, eradicating H. pylori and reducing ulcer recurrence. RBC H. pylori Study Group. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791947
|
Delchier JC et al. |
Omeprazole-amoxycillin versus omeprazole-amoxycillin-clarithromycin in the eradication of Helicobacter pylori. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8791948
|
Zullo A et al. |
Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. |
2007 |
Aliment. Pharmacol. Ther. |
pmid:17539982
|
Nista EC et al. |
Bacillus clausii therapy to reduce side-effects of anti-Helicobacter pylori treatment: randomized, double-blind, placebo controlled trial. |
2004 |
Aliment. Pharmacol. Ther. |
pmid:15569121
|
Harris AW et al. |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971302
|
Moshkowitz M et al. |
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971304
|
Wang WH et al. |
High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. |
2000 |
Aliment. Pharmacol. Ther. |
pmid:10886046
|
Laine L et al. |
Randomized comparison of differing periods of twice-a-day triple therapy for the eradication of Helicobacter pylori. |
1996 |
Aliment. Pharmacol. Ther. |
pmid:8971306
|